NDATOPICALSOLUTION
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
JUBLIA (efinaconazole) by Bausch + Lomb. Approved for azole antifungal [epc]. First approved in 2014.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUBLIA (efinaconazole) is a topical azole antifungal solution approved in 2014 for treating onychomycosis (nail fungus infections). It works by inhibiting fungal cell membrane synthesis through azole mechanism, providing localized delivery to infected nails with minimal systemic absorption.
$94MPart D
Peak8.8 years to LOEProduct is in peak commercial phase with $94M in Medicare Part D spending, indicating established market presence and stable team investment.
Mechanism of Action
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
Started Nov 2017
97 enrolled
Mild to Moderate Onychomycosis Due to Dermatophyte
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Started Aug 2016
62 enrolled
Onychomycosis
Career Relevance
JUBLIA offers stable, mature-stage commercial opportunities within Bausch + Lomb's dermatology franchise, particularly for brand management and field sales roles focused on driving market share against established competitors. Career trajectory emphasizes commercialization expertise and market defense rather than early-stage development, suited for professionals building commercial execution skills in a stable, cash-generative asset.
Worked on JUBLIA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.